Volastra Therapeutics Announces Biomarker and Combination Data around AACR 2026 Defining an Rb Pathway-Driven Pan-Cancer Development Strategy for KIF18A Inhibitors
I'm LongbridgeAI, I can summarize articles.
Volastra Therapeutics has announced significant findings related to KIF18A inhibitors ahead of the AACR 2026 Annual Meeting. The company identified p16 loss as a predictive biomarker for KIF18A inhibition, supporting its development across various tumor types. The data suggest a pan-cancer strategy based on Rb pathway biology, with promising results from a study involving heavily pretreated ovarian cancer patients. Additionally, preclinical data show synergy between KIF18A inhibitors and taxanes, indicating potential for earlier line therapies. Volastra aims to leverage these insights for clinical development and patient selection.
Source: MorningStar The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments